Cbf-β在骨关节炎发病中的研究概况

Overview of the Research of Cbf-β in the Onset of Osteoarthritis

摘要: 骨关节炎(OA)是我国最常见的骨关节炎，是老年人活动能力受损的主要原因之一，占慢性中度至重度疼痛的三分之一以上。OA是一种累及关节及其周围组织的慢性疾病，主要导致关节软骨进行性损伤，进而导致软骨下骨和周围滑膜结构损伤。尽管受OA影响的人数逐年增多，但目前仍无法延缓OA的进展，主要治疗方案集中在缓解症状，关节置换术是最终结局。深入探讨分子靶点的作用在研究药物开发的过程中至关重要。特别是，Cbf-β作为一种与Runx2结合形成异质二聚体的共转录因子，不仅增强了Runx2与DNA的结合力，还通过阻止Runx2的泛素化来维持其稳定性，因此在软骨内骨化过程中的作用比膜内骨化更为显著。本文综述了与Cbf-β和骨关节炎发展相关的最新研究成果，并探讨了Cbf-β作为治疗目标的可能性。这些发现强调了深入理解分子机制对于开发新的治疗策略的重要性，并指出了Cbf-β在骨科疾病治疗领域内的潜在价值。

Abstract: Osteoarthritis (OA) is the most common osteoarthritis in China. It is one of the main causes of impaired mobility in the elderly, accounting for more than one-third of chronic moderate to severe pain. OA is a chronic disease involving joints and surrounding tissues, which mainly leads to progressive damage to joint cartilage, which in turn leads to structural damage to the lower cartilage and peripheral synovial membrane. Although the number of people affected by OA has increased year by year, it is still impossible to delay the progress of OA. The main treatment plan focuses on relieving symptoms, and joint replacement is the final result. It is very important to deeply explore the role of molecular targets in the process of drug development. In particular, Cbf-β, as a co-recording factor bound to Runx2 to form a heterogeneous dimer, not only enhances the binding force of Runx2 to DNA, but also maintains its stability by preventing the ubiquitinization of Runx2. Therefore, it plays a more significant role in the process of cartilage ossification than intramembrane ossification. This article reviews the latest research results related to the development of Cbf-β and osteoarthritis, and discusses the possibility of Cbf-β as a treatment target. These findings emphasize the importance of an in-depth understanding of molecular mechanisms for the development of new treatment strategies, and point out the potential value of Cbf-β in the field of orthopedic disease treatment.